Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Millipore expands drug development facilties

This article was originally published in Scrip

Executive Summary

Millipore, a US-based biopharmaceutical manufacturing company, will expand its drug discovery facility in St Charles, Missouri. The $3.4 million expansion will see the company hire an additional 60 employees to add to the 187 that already work at the St Charles facility. Millipore is seeking certification from the Leadership in Energy and Environmental Design (LEED) green building rating system for the expanded 17,000sq ft space, where it will build new laboratories, administrative offices and an enlarged break area. In 2006, Millipore acquired Serologicals Corporation for $1.4 billion, which itself had previously acquired Cytomyx, one of the industry's largest suppliers of ion channel cell lines (ScripNo 3155, p 14).

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel